Premium
Medication contaminants as a potential cause of anaphylaxis to vincristine
Author(s) -
Hill David A.,
Leahy Allison Barz,
Sciasci Joseph,
O'Neill Sean P.,
Reilly Anne,
Balamuth Naomi,
Seeholzer Steven H.,
Spergel Jonathan M.,
BrownWhitehorn Terri F.
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26761
Subject(s) - medicine , anaphylaxis , vinca , vincristine , vinca alkaloid , adverse effect , anesthesia , intensive care medicine , pharmacology , chemotherapy , allergy , immunology , cyclophosphamide
Abstract Vincristine (VCR) is a vinca alkaloid and common chemotherapeutic that is used to treat multiple pediatric and adult malignancies. Despite its common use, cases of anaphylaxis to VCR are rare and typically isolated to a single individual. We report a series of eight patients with adverse reactions to VCR over the course of 11 months at a single institution, four of which progressed to anaphylaxis and one of which resulted in cardiac arrest. Mass spectrometry analysis of medication lots was performed to test for possible contaminant(s). Our findings highlight the risk of anaphylaxis during therapy with VCR.